Cardiac Dimensions company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cardiacdimensions.com

Founded Year

2000

Stage

Series C | Alive

Total Raised

$179.76M

Last Raised

$17.5M | 2 yrs ago

About Cardiac Dimensions

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Frankfurt, Germany.

Cardiac Dimensions Headquarter Location

5540 Lake Washington Blvd. NE

Kirkland, Washington, 98033,

United States

425-605-5910

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Cardiac Dimensions

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cardiac Dimensions in 1 CB Insights research brief, most recently on Mar 12, 2020.

Expert Collections containing Cardiac Dimensions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardiac Dimensions is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health IT

7,900 items

Cardiac Dimensions Patents

Cardiac Dimensions has filed 47 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Cardiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/17/2019

5/3/2022

Cardiac anatomy, Cardiac surgery, Cardiology, Valvular heart disease, Congenital heart defects

Grant

Application Date

9/17/2019

Grant Date

5/3/2022

Title

Related Topics

Cardiac anatomy, Cardiac surgery, Cardiology, Valvular heart disease, Congenital heart defects

Status

Grant

Latest Cardiac Dimensions News

Cardiac Dimensions begins pivotal trial for Carillon Mitral Contour System

Aug 23, 2021

23 Aug 2021 (Last Updated August 23rd, 2021 15:49) The trial, set to involve 300 patients at up to 75 sites, will compare the non-surgical device to optimal medical management. Share Article The Carillon Mitral Contour System is developed to treat heart failure patients with early-stage functional mitral regurgitation. Credit: StockSnap / Pixabay. Cardiac Dimensions has launched the pivotal EMPOWER trial to evaluate its Carillon Mitral Contour System to treat heart failure patients suffering from early-stage functional mitral regurgitation (FMR). The non-surgical device is developed to address mitral valve insufficiency safely and effectively. It is claimed to be the only indirect transcatheter mitral valve repair (TMVr) treatment device intended to generate an annuloplasty effect, start left ventricular remodelling and improve long-term survival for patients. The blinded, randomised EMPOWER study will assess the device compared to a sham-controlled group receiving optimal medical management according to established heart failure guidelines. Based on evaluations of results from more than 250 participants, who were part of four similar trials, and Cardiac Dimensions’ recent publications, the trial targets a large population of heart failure patients with FMR who have limited treatment options. The company plans to use third-party monitoring, core lab reviews and external safety reviews similar to previous trials. This approach is expected to help gather the most rigorous clinical data so far in this patient population. EMPOWER national principal investigator and Cleveland Clinic Department of Cardiovascular Medicine chairman Samir Kapadia said: “This will be the first time where we are able to study early intervention with a device in heart failure. The Carillon device will be used to treat heart failure patients with mild and moderate functional mitral regurgitation. “This is an extremely large patient population that is currently not being studied by other novel therapies. It will be phenomenal to study the efficacy of the Carillon device in the EMPOWER trial – a rigorously designed, randomised, double-blinded and sham-controlled multicentre clinical trial.” Cardiac Dimensions expects to enrol 300 patients at up to 75 sites for the EMPOWER trial. The study will assess primary safety and efficacy goals at 12 months as well as involving a follow-up of five years to capture long-term safety and clinical status. Related Companies

Cardiac Dimensions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cardiac Dimensions Rank

You May Also Like

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

Ancora Heart Logo
Ancora Heart

Ancora Heart is developing a therapy to address heart failure. Ancora Heart's AccuCinch Ventricular Repair System is a minimally invasive investigational treatment for heart failure and functional mitral regurgitation (FMR).

V
Viacor

Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.

C
Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

C
CoRepair

CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Mitralign Logo
Mitralign

Mitralign is developing a catheter-based technology for percutaneous treatment of functional mitral regurgitation. The Mitralign system emulates surgical annuloplasty delivering a series of surgical implants directly into the mitral annulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.